688202 Stock Overview
A drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shanghai Medicilon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥33.68 |
| 52 Week High | CN¥69.51 |
| 52 Week Low | CN¥23.30 |
| Beta | 0.80 |
| 1 Month Change | -13.40% |
| 3 Month Change | 38.94% |
| 1 Year Change | -48.88% |
| 3 Year Change | -84.47% |
| 5 Year Change | 13.64% |
| Change since IPO | -7.02% |
Recent News & Updates
Shareholder Returns
| 688202 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -6.3% | -1.5% | -1.2% |
| 1Y | -48.9% | -18.1% | 11.8% |
Return vs Industry: 688202 underperformed the CN Life Sciences industry which returned -19% over the past year.
Return vs Market: 688202 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 688202 volatility | |
|---|---|
| 688202 Average Weekly Movement | 12.3% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688202's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688202's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2,415 | Chunlin Chen | www.medicilon.com.cn |
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems.
Shanghai Medicilon Inc. Fundamentals Summary
| 688202 fundamental statistics | |
|---|---|
| Market cap | CN¥4.50b |
| Earnings (TTM) | -CN¥276.79m |
| Revenue (TTM) | CN¥984.17m |
4.6x
P/S Ratio-16.3x
P/E RatioIs 688202 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688202 income statement (TTM) | |
|---|---|
| Revenue | CN¥984.17m |
| Cost of Revenue | CN¥993.60m |
| Gross Profit | -CN¥9.43m |
| Other Expenses | CN¥267.35m |
| Earnings | -CN¥276.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.07 |
| Gross Margin | -0.96% |
| Net Profit Margin | -28.12% |
| Debt/Equity Ratio | 11.3% |
How did 688202 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 06:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Medicilon Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |
| Tao Fu | Topsperity Securities |